China OKs Hemophilia B Trial Testing BBM-H901 Gene Therapy

China OKs Hemophilia B Trial Testing BBM-H901 Gene Therapy

302776

China OKs Hemophilia B Trial Testing BBM-H901 Gene Therapy

Belief Biomed is launching a Phase 1/2 clinical trial in China to test BBM-H901, its investigational one-time gene therapy for hemophilia B. The announcement comes after China’s National Medical Products Administration (NMPA) approved the company’s investigational new drug application, which had been submitted in April, Belief Biomed said in a press release. According to the company, this is the first investigational new drug approval for an intravenous (into-the-vein) infusion gene therapy for hemophilia B in…

You must be logged in to read/download the full post.